Ipamorelin Peptides

Ipamorelin is a penta-peptides hormone. It has similar properties of GHRP-2, it does not have ghrelin's lipogenic properties and does not promote hunger. Ipamorelin acts synergistically when applied during a Releasing Hormone (GHRH) pulse or when it is used along with a GHRH such as Sermorelin or Modified GRF 1-29 (growth releasing factor, aminos 1-29). The synergy comes both due to the suppression of somatostatin and the fact that ipamorelin increases GH release per-somatotrope, while GHRH increases the number of somatotropes releasing GH. On the other hand, Ipamorelin is similar to GHRP-6 in that they both release GH at a very similar strength minus the side effects that of GHRP-6. Both GHRP-2 and GHRP-6 cause a release and an increase in cortisol and prolactin levels, however Ipamorelin only selectively releases GH at any dose. Ipamorelin shares similar function to Hexarelin and compared to other peptides, it is a much more steady form of ghrelin and has longer half-life periods of at least two hours long and causes secondary effect by making neurons to become excited. 

Application: 
Ipamorelin has demonstrated good safety and tolerability in human clinical studies. Research has shown that Ipamorelin is hormone specific which means that the pituitary hormones such as cortisol are unaffected. In a study, it was found that young female adult rats had increased bone mass due to 12 weeks of treatment with ipamorelin. This peptide compared to other Hormone Releasing Peptides ensures the benefits without having to deal with possible negative side effects. 

After an aggressive dosage of ipamorelin, the pituitary gland reacted by reducing the plasma growth hormone levels as opposed to how unchanged they were after comparable dosages of GHRH. This is another positive thing since it proves that ipamorelin will not reduce the production of natural growth hormones overall. This also proves that ipamorelin is a selective growth hormone releaser.